Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $230
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $225 to $230.
Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $225 to $230.